The Battle for This Huge Market Just Got Hotter

With Zimmer's acquisition of Biomet, this orthopedics company rises into the top tier of device makers and squares off against some formidable rivals.

Apr 25, 2014 at 6:30PM

The orthopedics industry's become a huge force in health care as populations in some of the world's biggest markets age and experience wear and tear on joints. Companies like Zimmer Holdings (NYSE:ZMH) and Stryker (NYSE:SYK) have reaped billions of dollars in revenue from orthopedics devices, and new, innovative technologies such as MAKO Surgical's RIO robotic surgical system, which Stryker snapped up in its acquisition of the company last year, are bringing new frontiers into this massive market.

Among the top companies, however, competition's fierce -- and Zimmer only added fuel to the fire of this war for dominance on Thursday when it announced an industry-shaking acquisition of rival Biomet. The big-time buy vaults Zimmer into the discussion of the top company in orthopedics, but will Biomet help Zimmer's stock outrun its rivals in the long term?

Zimmer's big play for the future
Zimmer forked over more than $13 billion in cash and stock in Thursday's deal for Biomet that shook up the market. It's an industry-shaking move: Combined, the two companies reported revenue of around $7.8 billion, placing the new Zimmer in the same class as Stryker and Johnson & Johnson's (NYSE:JNJ) DePuy as the clear-cut leaders by sales in the orthopedics industry. Previously, Zimmer had been the fourth-largest orthopedics producer; analysts expect that the merger will propel the company to the second spot behind only J&J. Investors certainly rallied behind the stock, sending shares shooting up more than 11% and turning Zimmer into one of the best buys among the top orthopedics device leaders over the past year.

ZMH Chart

ZMH data. Source: YCharts.

It's also promising for Zimmer's future outlook. While it will naturally see a boost to earnings in the year following the deal's close, Zimmer also projects that it will gain $270 million in savings in the third year and beyond following the acquisition. That'll help the company as it works toward improving profitability, something it failed to do last year as its operating margin declined by a full percentage point even as it lowered R&D and SG&A costs.

For investors and this stock, however, it's crucial that Zimmer capture the synergies of the Biomet acquisition particularly in its reconstructive orthopedics division. The business makes up around three-fourths of Zimmer's overall sales, split between knee, hip, and extremities products -- each of which has managed to ride the demographic trends buoying the market's optimism to respectable annual growth in sales last year.

Jj Logo

Will the top orthopedics players fire back?
Still, Zimmer has its work cut out for it. Competition will only grow hotter as the company's acquisition puts pressure on competitors to generate growth of their own, whether organically or through buyouts. Acquisitions, after all, spurred the growth of Johnson & Johnson's own medical device business when it purchased orthopedics and trauma products producer Synthes in 2011 for more than $21 billion. The synergies from that deal have powered orthopedics to the top of J&J's device business and managed 2.5% year-over-year growth in the most recent quarter.

While J&J likely will be content to remain in its top position in the orthopedics industry, Stryker and Smith & Nephew (NYSE:SNN) could be more active following Zimmer's deal. Stryker's already made big moves on the buyout front lately, from the MAKO buy to ride the cutting edge of the industry to last year's purchase of China's Trauson Holdings, giving Stryker an easy route into the world's second-largest economy. Smith & Nephew's also been active on the international front, with its emerging markets division now making up a full 13% of total revenue after 18% sales growth in 2013. Biomet's buyout has raised consideration now among analyst groups that Smith & Nephew could be the acquisitions target of Stryker or J&J in the near future, and Zimmer will need to keep growth churning along in order to keep up.

It's overseas that Zimmer investors need to keep a close eye on. China's orthopedics market has averaged around 20% compound annual growth in past years, and growth's likely to remain high with the rise of urbanization and the middle class in the country. Meanwhile, Zimmer's Asia-Pacific revenue in knee and hip reconstructive products fell in 2013, a trend it will need to turn around to keep geographic growth on course and investors happy about its future in emerging markets.

A fight for market share intensifies
While Zimmer still has work to do to show it can keep up with the likes of J&J's DePuy unit, the acquisition of Biomet plants this medical device leader squarely among the giants of the orthopedics industry. Demographic trends in the U.S., Europe, Japan, and China -- if Zimmer can capture that last market -- will only keep the market growing for the company and its rivals. As the market concentrates on the biggest players -- a trend that could be exacerbated should Stryker or J&J move on a Smith & Nephew acquisition in the coming years -- Zimmer will have to fight tooth and nail for market share. The buyout of Biomet's a good first step, but it's only the beginning for this device leader.

Will this stock be your next 10-bagger?
Savvy investors are always on the hunt for stocks that could boom like Zimmer did on Thursday, but one pick in particular could rule the market this year. Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. It also owns shares of Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers